Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis

Catalysts

About Caris Life Sciences

Caris Life Sciences is a precision medicine company focused on whole exome, whole transcriptome and whole genome sequencing across tissue and blood to inform cancer therapy selection, monitoring and early detection.

What are the underlying business or industry changes driving this perspective?

• Growing clinical adoption of comprehensive genomic profiling, with Caris now reaching about 6,000 oncologists and close to 2,800 EHR integrated sites, can support steady case volumes and a higher mix of orders coming in electronically, which is relevant for sustaining revenue and keeping unit costs contained to support gross margins.
• Broader use of liquid biopsy for therapy selection and concurrent tissue plus blood testing, where about 40% of blood cases already have a paired tissue profile, can deepen revenue per patient over time while spreading fixed lab costs across more billable profiles, which matters for both revenue and adjusted EBITDA.
• Expansion into MRD and monitoring, using the same whole exome and whole transcriptome platform that is already in commercial use, can add new testing occasions per patient without requiring a completely new commercial channel. This can influence revenue growth while helping protect net margins through shared infrastructure.
• Development of multi cancer early detection built on large ACHIEVE studies and whole genome sequencing, initially with self pay pricing, can open an additional testing category that is not tied to the same reimbursement cycles as current clinical profiling. This can diversify revenue streams and help smooth earnings volatility.
• Ongoing adoption of AI across a data set of more than 959,000 genomic profiles and over 1,150 peer reviewed publications can support new assays like MI Clarity and MRD signatures, giving Caris more content to monetize through both clinical testing and pharma work, which is relevant for sustaining revenue, maintaining high gross margins and supporting free cash flow.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Caris Life Sciences's revenue will grow by 27.6% annually over the next 3 years.
• Analysts assume that profit margins will increase from -105.1% today to 15.3% in 3 years time.
• Analysts expect earnings to reach $206.4 million (and earnings per share of $0.69) by about January 2029, up from $-681.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $329.0 million in earnings, and the most bearish expecting $91.2 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 67.0x on those 2029 earnings, up from -11.2x today. This future PE is greater than the current PE for the US Biotechs industry at 21.1x.
• Analysts expect the number of shares outstanding to grow by 1.52% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.1%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Caris is leaning heavily into whole exome, whole transcriptome and now whole genome sequencing. If oncologists, payers or regulators prefer simpler or cheaper panels over time, test adoption or pricing could be pressured, which would affect revenue growth and gross margins.
• The current uplift in clinical average selling prices for tissue and blood profiling is helped by a new CMS rate and recent reimbursement true ups. If commercial payers tighten coverage, reimbursement rates reset, or true ups normalize faster than expected, the company could see pressure on revenue and net margins.
• The long term thesis depends on new areas like MRD, monitoring and multi cancer early detection. Any delays in CMS coverage, lower than expected pricing, or slower physician uptake in these newer categories could limit the contribution from these pipelines and weigh on earnings.
• Management is signaling a willingness to reinvest aggressively rather than targeting very high EBITDA margins. Heavier spending on whole genome early detection, sales and marketing or external opportunities could cap profitability and reduce free cash flow even if top line revenue continues to grow.
• Therapy selection, MRD and early detection are all competitive markets. If rival platforms secure more companion diagnostic partnerships, better data sets, or faster regulatory progress, Caris could lose share or pricing power, which would impact revenue and long term earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $38.11 for Caris Life Sciences based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $45.0, and the most bearish reporting a price target of just $30.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.3 billion, earnings will come to $206.4 million, and it would be trading on a PE ratio of 67.0x, assuming you use a discount rate of 7.1%.
  
• Given the current share price of $26.98, the analyst price target of $38.11 is 29.2% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.